
Annovis Bio’s Breakthrough in Parkinson’s Treatment: New Drug Buntanetap Shows Promise
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) recently disclosed the encouraging results of its Phase III clinical trial related to Parkinson’s disease treatment. The experimental drug, buntanetap, has shown …
Annovis Bio’s Breakthrough in Parkinson’s Treatment: New Drug Buntanetap Shows Promise Read More